The current healthcare and life sciences sector offers opportunities for innovative companies to introduce new products and gain market share.
We can help you to focus on strategic and commercial matters whilst limiting potential liabilities. Our Life Sciences team combines legal expertise, commercial insight and scientific understanding to provide you with a solutions-focused service. We will work alongside you advising on any issues from transfer agreements to complex and technical patent litigation.
Our clients include cutting-edge businesses engaged in research, manufacturing, sales and distribution. We also work with colleges and universities, business incubators, research organisations, clinical trial providers, entrepreneurs and successful inventors.
Meet the team
Charles Russell Speechlys advises Apposite Capital on acquisition of i2a Diagnostics
i2a is a leading provider of laboratory instruments, software and reagents for the clinical microbiology market in France.
Levelling Up Life Sciences?
Charles Russell Speechlys advises Emergex Vaccines on $11m fundraising
Emergex is a UK-based biotechnology company and pioneers of developing synthetic ‘set point’ vaccines .
Charles Russell Speechlys advises CareTech on the acquisition of Smartbox
Smartbox is a market-leading creator of software and hardware that helps disabled people without speech to live more independently.
Charles Russell Speechlys advises Wimbledon NeuroCare and Ascot Rehabilitation on the acquisition of a healthcare diagnostic centre
Both Ascot Rehab and Wimbledon NeuroCare provide high quality rehabilitation services for people with neurological conditions.
The Life Sciences sector continues to thrive
Charles Russell Speechlys advises Apposite Capital on their investment into Mirada Medical
Mirada is a leading AI software developer for streamlining cancer treatment planning applications.
Charles Russell Speechlys advises Vapotherm on the acquisition of Solus Medical
Vapotherm is a publicly traded developer and manufacturer of advanced respiratory technology.
Charles Russell Speechlys advises Kreos and SVB on £20m growth capital investment to Mereo BioPharma
We advised Kreos Capital and Silicon Valley Bank on the refinancing of £20 million growth capital investment to Mereo BioPharma Group
Charles Russell Speechlys appointed as legal advisors to Hextransforma Healthcare
Hextransforma are a UK provider of digital healthcare solutions.
Charles Russell Speechlys advise Apposite Capital on investment into OrthoD Group
OrthoD is a specialist manufacturer and distributor of medical products and implants.
Charles Russell Speechlys advises on the sale of Xstrahl to Risk Capital Partners
Xstrahl is a leading designer and manufacturer of superficial orthovoltage X-ray systems.
Charles Russell Speechlys advises Kreos Capital on its €15 million growth capital investment
Kiadis Pharma is a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations safer.
Charles Russell Speechlys advises Kreos Capital and Silicon Valley Bank on growth capital investment to Mereo BioPharma
Mereo BioPharma is a UK-based specialty bio-pharmaceutical company listed on the AIM market of the London Stock Exchange.